Literature DB >> 13428909

Studies on the capacity of some polysaccharides to elicit antibody formation in man.

P Z ALLEN, E A KABAT.   

Abstract

Purified levan is antigenic in man and subcutaneous injection of 1 mg. leads to the production of precipitins and skin sensitivity. Apple amylopectin, maize glycogen, and synthetic polyglucose did not stimulate antibody production in small numbers of individuals injected. Quantitative precipitin studies carried out with several levan preparations employing human antilevan show variations in immunochemical behavior indicating structural differences among levans. Evidence that precipitins formed in response to levan injection are antilevan antibodies was obtained by analysis of specific precipitates formed in the region of antibody excess for ketosugar. Injection of levan giving rise to production of antilevan failed in one individual to give a non-specific anamnestic rise in either antidextran or antiblood group A precipitins. Laminarin, a neutral polysaccharide, was found to give precipitation with normal human sera.

Entities:  

Keywords:  ANTIBODIES; POLYSACCHARIDES/effects

Mesh:

Substances:

Year:  1957        PMID: 13428909      PMCID: PMC2136702          DOI: 10.1084/jem.105.5.383

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  The influence of Aerobacter levan on the permeability of the blood vessels of the skin: studies with antibody globulins and trypan blue.

Authors:  A M DAVIES; M SHILO; S HESTRIN
Journal:  Br J Exp Pathol       Date:  1955-10

2.  Heterogeneity in dextran preparations.

Authors:  C A WILHAM; B H ALEXANDER; A JEANES
Journal:  Arch Biochem Biophys       Date:  1955-11       Impact factor: 4.013

3.  Dextran; an antigen in man.

Authors:  E A KABAT; D BERG
Journal:  J Immunol       Date:  1953-06       Impact factor: 5.422

4.  The reaction of H-substance with rabbit antisera.

Authors:  R G S JOHNS; J R MARRACK
Journal:  J Hyg (Lond)       Date:  1953-03

5.  Immunochemical studies on the specific polysaccharide of type II Pneumococcus.

Authors:  S B BEISER; E A KABAT; J M SCHOR
Journal:  J Immunol       Date:  1952-09       Impact factor: 5.422

6.  Dextran, an antigen in man.

Authors:  P H MAURER
Journal:  Proc Soc Exp Biol Med       Date:  1953 Aug-Sep

7.  IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS : III. PROPERTIES OF PURIFIED BLOOD GROUP A SUBSTANCES FROM INDIVIDUAL HOG STOMACH LININGS.

Authors:  A Bendich; E A Kabat; A E Bezer
Journal:  J Exp Med       Date:  1946-05-31       Impact factor: 14.307

8.  IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS : XI. SPECIES DIFFERENCES AMONG BLOOD GROUP A SUBSTANCES.

Authors:  E A Kabat; H Baer; R L Day; V Knaub
Journal:  J Exp Med       Date:  1950-03-31       Impact factor: 14.307

9.  FORMATION OF SEROLOGICALLY REACTIVE DEXTRANS BY STREPTOCOCCI FROM SUBACUTE BACTERIAL ENDOCARDITIS.

Authors:  E J Hehre; J M Neill
Journal:  J Exp Med       Date:  1946-01-31       Impact factor: 14.307

10.  ANTIBODY FORMATION IN VOLUNTEERS FOLLOWING INJECTION OF PNEUMOCOCCI OR THEIR TYPE-SPECIFIC POLYSACCHARIDES.

Authors:  M Heidelberger; C M Macleod; S J Kaiser; B Robinson
Journal:  J Exp Med       Date:  1946-03-31       Impact factor: 14.307

View more
  4 in total

1.  [Mechanisms of nonspecific infection resistance].

Authors:  D BOHME
Journal:  Klin Wochenschr       Date:  1958-09-15

2.  Studies on immunological paralysis. IX. The immunogenicity and tolerogenicity of levan (polyfructose) in mice.

Authors:  J J Miranda
Journal:  Immunology       Date:  1972-12       Impact factor: 7.397

3.  Immunochemical studies on mouse myeloma proteins reactive with dextrans or with fructosans and on human antilevans.

Authors:  J Cisar; E A Kabat; J Liao; M Potter
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

4.  Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran.

Authors:  J Cisar; E A Kabat; M M Dorner; J Liao
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.